SCHOTT, a global pioneer in specialty glass, has announced the addition of syringe and cartridge glass tubing to its existing state-of-the-art manufacturing capabilities in Jambusar, Gujarat.
This marks a significant milestone in India's glass primary pharmaceutical packaging landscape and reinforcing SCHOTT's commitment to the 'Make in India' initiative. This strategic action positions the company as Asia's largest producer of syringe and cartridge glass tubing.
The cutting-edge production is a direct technology transfer from SCHOTT's renowned German expertise. It is set to meet the surging demand for biologics like semaglutide (belonging to the GLP-1 receptor agonist class) used for weight management and control of blood sugar levels in patients with type 2 diabetes.
As per experts, the GLP-1 segment alone is projected to witness a staggering CAGR of 33%. Also administered in a pre-filled syringe or cartridge, this launch positions SCHOTT in India to fully cater to all glass primary packaging needs of pharma, from glass tubing for vials and ampoules to the newly added syringes and cartridges.
The precise inner diameter tolerance of syringe glass tubing can ensure plunger tightness and consistent gliding forces on the inner surface of the entire length during administration of the drug. SCHOTT’s Type I borosilicate glass tubing, FIOLAX®, has consistent wall thickness and very tight geometric precision and tolerance especially for the inner diameter which makes it the perfect fit for prefillable syringes and cartridges.
Image caption- Pawan Kumar Shukla, Managing Director and President, SCHOTT Glass Pvt. Ltd (L) and Sundeep Prabhu, Senior Vice President – Sales and Marketing, SCHOTT Glass Pvt. Ltd (R)
